Tg Therapeutics (TGTX) Free Cash Flow (2011 - 2026)

Tg Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$17.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 37.56% year-over-year to -$17.9 million in Q1 2026; TTM through Mar 2026 was -$14.2 million, a 76.77% increase from a year earlier, with the FY2025 full-year figure at -$25.0 million, up 38.4% from the prior year.
• Free Cash Flow eased to -$17.9 million in Q1 2026 per TGTX's latest filing, from $19.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $83.7 million in Q3 2023 and bottomed at -$68.7 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$23.2 million (2025), against an average of -$17.1 million.
• Across the five-year window, Free Cash Flow surged 342.63% in 2023 and slumped 250.19% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$23.9 million in 2022, then soared by 44.67% to -$13.2 million in 2023, then plunged by 94.26% to -$25.7 million in 2024, then surged by 176.35% to $19.6 million in 2025, then slumped by 191.59% to -$17.9 million in 2026.
• Per Business Quant, the three latest TGTX Free Cash Flow figures stand at -$17.9 million (Q1 2026), $19.6 million (Q4 2025), and -$23.2 million (Q3 2025).